Cannabidivarin Explained

Cannabidivarin (CBDV, GWP42006) is a non-intoxicating psychoactive cannabinoid found in Cannabis. It is a homolog (chemistry) of cannabidiol (CBD), with the side-chain shortened by two methylene bridges (CH2 units).

Although cannabidivarin (CBDV) is usually a minor constituent of the cannabinoid profile, enhanced levels of CBDV have been reported in feral populations of C. indica (= C. sativa ssp. indica var. kafiristanica) from northwest India, and in hashish from Nepal.[1] =[2] [3]

CBDV demonstrated anticonvulsant in rodent models in a single published study.[4] It was identified for the first time in 1969 by Vollner et al.[5]

Similarly to CBD, it has seven double bond isomers and 30 stereoisomers (see: Cannabidiol#Isomerism). It is not scheduled by Convention on Psychotropic Substances. It is being actively developed by GW Pharmaceuticals (as GWP42006)[6] because of a demonstrated neurochemical pathway for previously observed anti-epileptic and anti-convulsive action.[7] GW has begun several Phase-2 trials for adult epilepsy,[8] for childhood epilepsy and for Prader-Willi Syndrome.[9] [10]

See also

External links

Notes and References

  1. Turner CE, Cheng PC, Lewis GS, Russell MH, Sharma GK . 1979 . Constituents of Cannabis sativa XV: Botanical and chemical profile of Indian variants . Planta Medica . 37 . 3 . 217–25 . 10.1055/s-0028-1097331. 83483599 .
  2. Hillig KW, Mahlberg PG . A chemotaxonomic analysis of cannabinoid variation in Cannabis (Cannabaceae) . American Journal of Botany . 91 . 6 . 966–975 . June 2004 . 21653452 . 10.3732/ajb.91.6.966 . free .
  3. Merkus FW . Cannabivarin and tetrahydrocannabivarin, two new constituents of hashish . Nature . 232 . 5312 . 579–580 . August 1971 . 4937510 . 10.1038/232579a0 . 4219797 . 1971Natur.232..579M .
  4. Hill AJ, Mercier MS, Hill TD, Glyn SE, Jones NA, Yamasaki Y, Futamura T, Duncan M, Stott CG, Stephens GJ, Williams CM, Whalley BJ . 6 . Cannabidivarin is anticonvulsant in mouse and rat . British Journal of Pharmacology . 167 . 8 . 1629–1642 . December 2012 . 22970845 . 3525866 . 10.1111/j.1476-5381.2012.02207.x .
  5. Vollner L, Bieniek D, Korte F . [Hashish. XX. Cannabidivarin, a new hashish constituent] . Tetrahedron Letters . 10 . 3 . 145–147 . January 1969 . 5778489 . 10.1016/S0040-4039(01)87494-3 .
  6. Web site: GW Pharmaceuticals Announces Preliminary Results of Phase 2a Study for its Pipeline Compound GWP42006 . GW Pharmaceuticals . 21 February 2018 . 28 May 2019.
  7. Amada N, Yamasaki Y, Williams CM, Whalley BJ . Cannabidivarin (CBDV) suppresses pentylenetetrazole (PTZ)-induced increases in epilepsy-related gene expression . PeerJ . 1 . e214 . 2013 . 24282673 . 3840466 . 10.7717/peerj.214 . free .
  8. GW Pharmaceuticals Initiates Phase 2 Clinical Study of Cannabidivarin (CBDV) in Epilepsy . GW Pharmaceuticals . May 6, 2015 . November 10, 2015 .
  9. Web site: GW Pharma Press release. https://web.archive.org/web/20151121025630/http://ir.gwpharm.com/releasedetail.cfm?ReleaseID=938568. 2015-11-21. dead.
  10. Web site: NSW advice to practitioners on Medical Cannabis trials. https://web.archive.org/web/20151121020442/http://www.health.nsw.gov.au/cannabis/Documents/medicial-cannabis-practitioners.pdf. 2015-11-21. dead.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Cannabidivarin".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.